The ubiquitin proteasome pathway is essential for the proliferation and survival of multiple myeloma (MM) cells. TAS4464, a novel highly potent inhibitor of NEDD8 activating enzyme, selectively inactivates cullin-RING ubiquitin E3 ligases, resulting in accumulation of their substrates. Here, we examined 14 MM cell lines treated with TAS4464. TAS4464 induced growth arrest and cell death in the MM cell lines even in the presence of bone marrow stromal cells. It also induced the accumulation of phospho-inhibitor of κBα and phospho-p100, impaired the activities of nuclear factor κB (NF-κB) transcription factors p65 and RelB, and decreased the expression of NF-κB target genes, suggesting that TAS4464 inhibits both the canonical and noncanonical NF-κB pathways. TAS4464 had similar effects in an in vivo human-MM xenograft mouse model in which it was also observed to have strong antitumor effects. TAS4464 synergistically enhanced the antitumor activities of the standard MM chemotherapies bortezomib, lenalidomide/dexamethasone, daratumumab and elotuzumab. Together, these results suggest that the anti-MM activity of TAS4464 occurs via inhibition of the NF-κB pathways, and that treatment with TAS4464 is a potential approach for treating MM by single and combination therapies. K E Y W O R D S molecular targeted therapy, multiple myeloma, NEDD8 activating enzyme, nuclear factor κB, ubiquitin-like protein NEDD8 | 3803 MURAOKA et Al.
| INTRODUC TI ON
Multiple myeloma (MM) is a type of blood cancer in which malignant plasma cells accumulate in the bone marrow and produce an abnormal antibody called M protein. In the past decade, several molecular-targeted agents and antibodies such as proteasome inhibitors (bortezomib, carfilzomib and ixazomib), immunomodulatory imide drugs (thalidomide and lenalidomide) and monoclonal antibodies (daratumumab and elotuzumab) have been approved for the treatment of relapsed MM. 1, 2 Although tively; p100 is the precursor of p52. Treatment of MM cells with proteasome inhibitors accumulates unfolded proteins in the endoplasmic reticulum and cytosol. 8 This accumulation triggers several pro-apoptotic factors and cell stress accumulation, leading to apoptosis. 9 Inactivation of NF-κB signaling activated in MM via accumulation of phospho-IκBα (p-IκBα) by blocking proteasomal degradation has been reported as another mechanism of action of a proteasome inhibitor in MM. 10 Conjugation of the ubiquitin-like protein NEDD8 to its target proteins (neddylation) occurs via a process very similar to ubiquitination, although the process requires different E1 and E2 proteins for ubiquitin activation and conjugation, respectively. NEDD8 activating enzyme E1 (NAE, a heterodimer comprising APPBP1 and UBA3 subunits), the first enzyme in the neddylation pathway, activates cullin-RING E3 ubiquitin ligases (CRL) thorough the neddylation of cullin proteins. Activated CRL conjugate ubiquitin to their substrates and promote ubiquitin-dependent degradation of their substrates by proteasomes. 11 CRL substrates include many key proteins essential for a diverse range of cellular processes, including cell cycle progression, DNA replication and signal transduction. Neddylation is considered an essential process for cancer progression because overexpression of NEDD8 and NAE have been reported in various cancers. [12] [13] [14] [15] Furthermore, elevated levels of NEDD8 transcripts are correlated with poor prognosis in bortezomib-treated MM patients. 16 Studies with the NAE inhibitor MLN4924 (pevonedistat) suggest that NAE is an attractive target for cancer intervention. 17 MLN4924 is reported to induce apoptosis in MM cells through suppression of PI3K/mTOR signaling via REDD1 accumulation. 18 TAS4464 is one of the most selective and potent NAE inhibitors reported to date both in vitro and in vivo. 19 TAS4464 exhibits widespread antiproliferative activity in various tumor cell lines and is especially active against most hematologic malignancy cell lines, including myeloma-derived cell lines. 19 In this study, we investigated the antitumor properties and mechanism of action of NAE inhibition by TAS4464 in MM cells, focusing on the perturbation of the NF-κB signaling that is activated in MM cells.
| MATERIAL S AND ME THODS

| Chemical compounds
TAS4464 was synthesized at Taiho Pharmaceutical. Bortezomib was purchased from LKT Laboratories. Lenalidomide was purchased from MedChemExpress. Dexamethasone was purchased from Kyoritsu Seiyaku. Daratumumab was purchased from Janssen-Cilag.
Elotuzumab was purchased from Bristol-Myers Squibb GmbH & Co.
KGaA. were obtained from the American Type Culture Collection. EMJ was cultured in Iscove's modified Dulbecco's medium supplemented with 20% FBS. HS-5 was cultured in DMEM supplemented with 10% FBS.
| Cell lines and cell culture
NCI-H929 was cultured in RPMI 1640 medium supplemented with 10% FBS and 0.05 mmol/L 2-mercaptoethanol. U266B1 was cultured in RPMI 1640 medium supplemented with 15% FBS. The other cell lines were cultured in RPMI 1640 medium supplemented with 10% FBS. All cell lines used were authenticated by means of short tandem repeat-based DNA profiling.
| Growth inhibition assay
Cells were treated with TAS4464 for 72 hours. Then, cell viability was measured by using the CellTiter-Glo 2.0 Assay (Promega). To assess the cytotoxicity of TAS4464, growth inhibition curves were generated in which the percentage of growth was determined with 
| Co-culture of myeloma and stromal cell lines
The human multiple myeloma cell line MM.1S was plated on preseeded monolayers of the human stromal cell line HS-5. After 24 hours of co-culture of MM.1S cells with HS-5 cells at 37°C in a humidified atmosphere containing 5% CO 2 , cells were treated with TAS4464 for 48 hours. Then, MM.1S and HS-5 cell viability were measured by using a Vi-CELL XR Cell Viability Analyzer (Beckman Coulter).
| Flow cytometric analysis
Cells were treated with TAS4464 and then fixed and stained by using a BD Cycletest Plus DNA Reagent Kit (BD Biosciences). Stained cells were analyzed by using a fluorescence-activated cell sorter (BD FACSVerse, BD Biosciences). were blocked with Blocking One or Blocking One P blocking reagent (Nacalai Tesque), then probed with the appropriate primary antibodies, which were diluted using 5% (v/v) Blocking One or Blocking One P in TBS supplemented with 0.05% (v/v) Tween 20 (TBS-T).
| Antibodies and western blotting
The membranes were then incubated with HRP-linked secondary antibodies (Cell Signaling Technology) that were diluted using 5% (v/v) Blocking One or Blocking One P in TBS-T. Proteins were visualized by means of luminol-based enhanced chemiluminescence (Thermo Fisher Scientific). Luminescent images were captured with an LAS-3000 imaging system (Fuji Photo Film) or Amersham Imager 600 (GE Healthcare Japan).
| Quantitative RT-PCR
TaqMan Gene Expression Assays (gene symbols and assay IDs are shown in Table S1 ) were purchased from Thermo Fisher Scientific.
Cells and tumors were treated with TAS4464 for the indicated times. Then, DNase-treated RNA was isolated from cells by using an RNeasy Plus Mini Kit (Qiagen). For the extraction of RNA from tumors, the excised tumor was soaked in ISOGEN (Nippon Gene) and then homogenized with Pellet Mixer for Microtubes 1.5 mL (Nolato Treff). DNase-treated RNA was isolated by using an RNeasy Plus Mini Kit. cDNA was synthesized by using SuperScript III First-Strand Synthesis SuperMix for quantitative RT-PCR (Thermo Fisher Scientific). Quantitative PCR (qPCR) was performed by using a 7900HT Fast Real-Time PCR System (Applied Biosystems) or a QuantStudio 7 Flex System (Thermo Fisher Scientific). Relative mRNA expression was calculated by using the comparative Ct method with the following formulae:
| Quantification of nuclear factor κB binding activation
Cells were treated with TAS4464 for 4 hours, and then nuclear extracts were prepared by using a Nuclear Extract Kit (Active Motif).
NF-κB binding to its consensus DNA site was quantified by using a TransAM NFκB Family Kit (Active Motif). Statistical significance was calculated by using Student's t test to assess the difference in NF-κB binding between the control and TAS4464-treated groups. P < 0.05 was considered statistically significant.
| In vivo efficacy studies
Multiple myeloma cells were subcutaneously implanted into male SCID mice (Charles River Laboratories Japan) and allowed to grow to over 100 mm 3 . Six animals were assigned to each group for each experiment, and TAS4464 formulated in 5% (w/v) glucose was administered intravenously twice a week at 50 or 100 mg/kg. Figure 1A and Table S2 ). In addition, at concentrations ≥ 100 nmol/L, TAS4464 increased the proportion of cells in the sub-G1 phase ( Figure S1 ). These results indicate that TAS4464 inhibits cell growth and induces apoptotic or mitotic cell death in MM cell lines.
| RE SULTS
| TAS4464 inhibits proliferation and induces apoptosis of multiple myeloma cells
It has been reported that the bone marrow microenvironment is important for the growth of MM cells and their resistance to many chemotherapies. [20] [21] [22] Therefore, we assessed the impact of stromal interactions on the sensitivity of MM cells to TAS4464.
MM.1S cells were co-cultured with HS-5 BMSC and then treated with 0-1000 nmol/L TAS4464 for 48 hours. The effects of TAS4464 on the viability of MM.1S cells were not attenuated by co-culture with BMSC ( Figure 1B) , even though TAS4464 had no effect on the viability of the HS-5 cells ( Figure 1C ). TAS4464 again increased the proportion of MM.1S cells in the sub-G1 phase, even in the presence of BMSC ( Figure 1D ; representative flow cytometry patterns are in Figure S2 ). Although adhesion of MM cells to BMSC upregulates the secretion of growth factors such as interleukin 6 and insulin-like growth factor 1 from BMSC, [23] [24] [25] [26] neither of these growth factors attenuated the antiproliferative activity of TAS4464 in MM.1S cells ( Figure S3 ). 
| TAS4464 downregulates both the canonical and non-canonical nuclear factor κB pathways in multiple myeloma cells
We have reported that TAS4464 inhibits the neddylation pathway via inhibition of NAE, which leads to accumulation of CRL substrates in several solid and hematologic tumor cell lines. 19 In the present study, TAS4464 also reduced the levels of neddylated UBC12 (an E2 for NEDD8) and neddylated cullin1 (a component of CRL) and selectively induced the accumulation of the CRL substrates p-IκBα, CDT1, NRF2 and p21, but not substrates of non-CRL E3s (GADD34 and PTTG), in MM.1S cells in a dose-dependent and time-dependent manner ( Figure S4 ).
We then examined whether TAS4464 could affect the NF-κB pathways activated in MM cells. Four MM cell lines were exposed was downregulated in all four tested MM cell lines ( Figure 2C ).
| TAS4464 downregulates the nuclear factor κB pathways and has antitumor activity in humanmultiple myeloma xenograft mouse models
To evaluate the pharmacodynamic response to TAS4464 and the expression of NF-κB-targeted genes in vivo, MM.1S and KMS-26 tumors were harvested from human-MM xenograft mouse models at 1, 4 or 24 hours after administration of TAS4464 at 100 mg/kg ( Figure 3) . In both models, TAS4464 decreased the level of neddylated cullin1 as early as 1 hour after administration. In addition, at 4 hours after administration, the levels of CRL substrates were increased, indicating that TAS4464 inhibited NAE in the MM tumors.
The levels of apoptosis-related factors (cleaved forms of caspase-8, caspase-3 and PARP) were also increased ( Figure 3A ). In addition, TAS4464 treatment downregulated NF-κB-targeted genes, suggesting downregulation of the NF-κB pathways following the accumulation of p-IκBα and p-p100 in tumors ( Figure 3B ).
In accordance with the inhibition of the NF-κB pathways in tumors, intravenous administration of TAS4464 at 50 or 100 mg/kg twice a week significantly inhibited tumor growth ( Figure 4 and Figure S5 ) without remarkable body weight loss ( Figure S6 ), whereas standard MM chemotherapies (ie, bortezomib, lenalidomide, dexamethasone, daratumumab and elotuzumab) showed weak tumor growth inhibition.
Next, we evaluated whether TAS4464 can be combined with the key MM chemotherapies bortezomib, lenalidomide/dexamethasone, daratumumab and elotuzumab. All combination groups demonstrated significantly greater tumor growth inhibition than each therapy alone ( Figure 4 ). In addition, there were no deaths or decreases in body weight of 15% or more in any of the groups, suggesting that all treatments were tolerable ( Figure S6 ). Together, these results indicate that TAS4464 shows marked anti-MM activity alone and enhanced anti-MM activity in combination with key MM chemotherapies.
| D ISCUSS I ON
In this study, we evaluated the anti-MM activity of a highly potent and selective NAE inhibitor, TAS4464, and examined how TAS4464 affects MM cells. We found that TAS4464 inhibited both the canonical and non-canonical NF-κB pathways, which led to strong antitumor activity in human-MM xenograft mouse models.
F I G U R E 3 In vivo pharmacodynamic activity of TAS4464
in human multiple myeloma xenograft mouse models. Pharmacodynamic activity of TAS4464 against MM.1S and KMS-26 xenograft models. SCID mice bearing MM.1S or KMS-26 (n = 3 mice per sampling point) were intravenously administered 100 mg/ kg TAS4464. At 1, 4 or 24 h after administration, the mice were killed and the tumors were harvested. Mice in the control group were untreated, and the tumors were harvested at the same time as those in the 1-h treatment group. A, Protein extracts (MM.1S, 20 µg; KMS-26, 30 µg) from tumors were subjected to western blot analysis. B, Total RNA (50 ng) from tumors were subjected to quantitative RT-PCR analysis and the levels of NF-κB-targeted gene transcripts were measured In MM cells, activation of the NF-κB pathways is caused by several genetic aberrations and extracellular signals, [3] [4] [5] [6] 27 with the canonical pathway activated mostly by extracellular signals, such as B-cell antigen receptor signaling and tumor necrosis factor receptor signaling, and the non-canonical pathway activated by cytokines. 28, 29 Although simultaneous inhibition of both the canonical and non-canonical pathways seems to be required to fully inactivate NF-κB function in MM cells, 30 the complexity of the many different molecular mechanisms involved in NF-κB activation makes this difficult. According to previous reports, 31, 32 the proteasome inhibitor bortezomib exerts its anti-MM activity through inhibition of the NF-κB pathways; however, it has been shown that bortezomib does not completely inhibit the NF-κB pathways in nonclinical and clinical samples. [33] [34] [35] For example, bortezomib is reported to inactivate the non-canonical NF-κB pathway, which inhibits the conversion of p100 to p52, and to enhance the activity of the canonical NF-κB pathway through downregulation of p-IκBα, 33 suggesting that bortezomib does not fully inactivate NF-κB function in MM cells. Indeed, we found that treatment with the maximum tolerated dose of bortezomib (1 mg/kg) determined by our evaluation did not completely inhibit NF-κB activity and had limited efficacy in KMS-26 tumors despite inhibiting proteasome activity ( Figure S7) . In contrast to bortezomib, we found in the present study that TAS4464 stabilizes the intrinsic NF-κB inhibitors p-IκBα and p-p100 through inactivation of their ubiquitin E3 ligase CRL, and inhibits NF-κB activity with strong anti-MM activity both in vitro and in vivo. This suggests that TAS4464 exerts its antitumor activity through inhibition of both the canonical and non-canonical NF-κB pathways in MM cells. However, this is different to the reported mechanism of action of another NAE inhibitor, MLN4924, which exerts its antitumor activity in MM cells through suppression of PI3K/mTOR signaling via REDD1 accumulation. 18 One possible explanation for this discrepancy is that suppression of the NF-κB pathways and of PI3K/mTOR signaling via NAE inhibition is time-dependent and/or dose-dependent. In four MM cell lines, we found that treatment with MLN4924 or TAS4464 for 4 hours reduced the levels of neddylated UBC12 and neddylated cullin1, and induced the accumulation of p-IκBα and p-p100, in a dose-dependent manner ( Figure S8A ). Both compounds also dose-dependently induced the expression of REDD1 protein, which is a key regulator of the PI3K/mTOR activity 18 ; however, the induction of REDD1 protein was slightly weaker than that of p-IκBα and p-p100, except in U266B1 cells. In all four cell lines, MLN4924 was almost 10-fold less active than TAS4464, based on the reduction of neddylated UBC12 and neddylated cullin1; that is, 1000 nmol/L of MLN4924, but only 100 nmol/L of TAS4464, Figure 2C ).
Further studies are needed to examine the extent to which the inhibition of each pathway is involved in the anti-MM activities of these compounds; however, MLN4924 rapidly increased the levels of p-IκBα and p-p100 in MM cells ( Figure S8 ) and is reported to inhibit the NF-κB pathway in other hematological malignancies such as diffuse large B-cell lymphoma and B-cell chronic lymphocytic leukemia. [36] [37] [38] [39] [40] Interactions of MM cells with other cells and the extracellular matrix in the bone marrow microenvironment are important for the progression and survival of MM cells. 41 In addition, these interactions play a crucial role in the drug resistance of MM cells. Indeed, the anti-MM activities of the conventional chemotherapies dexamethasone and doxorubicin have been shown to be suppressed by co-culture with BMSC, although that of bortezomib is reported to be unaffected under such conditions. 22 In the present study, we show that the effects of TAS4464 on MM cells were not weakened under conditions that mimic the bone marrow microenvironment (ie, under co-culture with BMSC or in the presence of cytokines), suggesting that TAS4464 has the potential to overcome the growth stimulatory effects triggered by microenvironmental signaling.
Because MM is a heterogeneous hematologic malignancy, MM patients usually receive combination therapy with two or more drugs that target different molecules. 42, 43 Importantly, we found that TAS4464 significantly inhibited tumor growth without remarkable toxicities not only as a single agent but also when it was administered in combination with the current standard therapies bortezomib, lenalidomide/dexamethasone, daratumumab and elotuzumab in human-MM xenograft mouse models. Because each standard therapy has a different mechanism of action, it is plausible that TAS4464 enhances the apoptosis induced by these other drugs through NF-κB inhibition. Although the molecular mechanisms by which TAS4464 enhanced these different types of drugs remain to be elucidated, TAS4464 has the potential to be used to treat MM in the clinic as a drug that can be combined with current standard chemotherapies.
In summary, TAS4464 showed antitumor activity in human-MM mouse models by inhibiting NF-κB activation in MM cells.
With TAS4464 affecting both the canonical and non-canonical NF-κB pathways, it demonstrated the potential to be used for the treatment of MM regardless of genetic background. TAS4464 may also overcome the growth stimulatory and anti-apoptotic effects triggered by microenvironmental signaling. We also found in human-MM xenograft mouse models that TAS4464 enhances the antitumor activities of current standard MM chemotherapies without remarkable toxicities. Together, these specific properties indicate that TAS4464 has the potential to be a valuable option in the treatment of MM either as a standalone or combination therapy, and that it may also improve the treatment of other NF-κBactivated cancers.
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